Advertisement
Advertisement
U.S. Markets open in 4 hrs 33 mins
Advertisement
Advertisement
Advertisement
Advertisement

Akero Therapeutics, Inc. (AKRO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.22+0.28 (+1.34%)
At close: 4:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close20.94
Open20.86
Bid0.00 x 800
Ask0.00 x 800
Day's Range20.64 - 21.25
52 Week Range17.66 - 34.87
Volume89,120
Avg. Volume182,792
Market Cap739.01M
Beta (5Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)-2.49
Earnings DateAug 10, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est56.71
  • SmarterAnalyst

    Akero Therapeutics’ NASH Treatment Gets Fast Track Designation; Shares Rise

    Akero Therapeutics (AKRO) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its non-alcoholic steatohepatitis (NASH) treatment, efruxifermin. Following the news, shares of AKRO rose 5.7% in the extended trading session on Tuesday. The stock was trading 9.6% higher, at the time of writing, in early trade on Wednesday. The California-based biotechnology company is engaged in the development of transformational treatments for NASH and other serious met

  • GlobeNewswire

    Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH

    SOUTH SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead program investigating efruxifermin (EFX) for the treatment of non-alcoholic steatohepatitis (NASH). The Fast Track designation facilitates the development of new drugs to

  • GlobeNewswire

    Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference

    SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that Tim Rolph, Akero’s Chief Scientific Officer and Co-Founder, will present at the H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12, 2021 at 12:00 p.m. (ET). A live webcast of the Company presentation will be available through the

Advertisement
Advertisement